News
Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns
SAN ANTONIO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice
COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium
COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
COLUMBUS, Ohio, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
COLUMBUS, Ohio, Sept. 13, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Top-Line Data From ELAINE 1 Phase 2 Study of Lasofoxifene Versus Fulvestrant Is Accepted for a Late-Breaking Oral Presentation at ESMO Congress 2022
COLUMBUS, Ohio, Aug. 25, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
COLUMBUS, June 09, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite...
Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting
COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
To sign up for future Sermonix press releases, please enter your information below.